José M. Zuniga

Dr. José M. Zuniga

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RGReuben Granich
Reuben Granich
SGSomya Gupta
Somya Gupta
BHBradley Hersh
Bradley Hersh
BWBrian Williams
Brian Williams
JMJulio Montaner
Julio Montaner
José M. ZunigaJosé M. Zuniga
José M. Zuniga
Antiretroviral therapy (ART) prevents human immunodeficiency virus (HIV) disease progression, mortality and transmission. We assess the impact of expanded HIV treatment for the prevention of Acquired Immunodeficiency Syndrome (AIDS)-related deaths and simulate four treatment scenarios for Nigeria and South Africa. For 1990–2013, we used the Joint United Nations Programme on HIV/AIDS (UNAIDS) database to examine trends in AIDS deaths, HIV incidence and prevalence, ART coverage, annual AIDS death rate, AIDS death-to-treatment and HIV infections to treatment ratios for the top 30 countries with the highest AIDS mortality burden and compare them with data from high-income countries. We projected the 1990–2020 AIDS deaths for Nigeria and South Africa using four treatment scenarios: 1) no ART; 2) maintaining current ART coverage; 3) 90% ART coverage based on 2013 World Health Organization (WHO) ART guidelines by 2020; and 4) reaching the United Nations 90-90-90 Target by 2020. In 2013, there were 1.3 million (1.1 million–1.6 million) AIDS deaths in the top 30 countries representing 87% of global AIDS deaths. Eight countries accounted for 58% of the global AIDS deaths; Nigeria and South Africa accounted for 27% of global AIDS deaths. The highest death rates per 1000 people living with HIV were in Central African Republic (91), South Sudan (82), Côte d’Ivoire (75), Cameroon (72) and Chad (71), nearly 8–10 times higher than the high-income countries. ART access in 2013 has averted as estimated 1,051,354 and 422,448 deaths in South Africa and Nigeria, respectively. Increasing ART coverage in these two countries to meet the proposed UN 90-90-90 Target by 2020 could avert 2.2 and 1.2 million deaths, respectively. Over the past decade the expansion of access to ART averted millions of deaths. Reaching the proposed UN 90-90-90 Target by 2020 will prevent additional morbidity, mortality and HIV transmission. Despite progress, high-burden countries will need to accelerate access to ART treatment to avert millions of premature AIDS deaths and new HIV infections.

19 March 2012 in Journal of the International Association of Physicians in AIDS Care
Verified
Journal Article
Closed access
PDF file
JNJean B. Nachega
Jean B. Nachega
CMChelsea Morroni
Chelsea Morroni
José M. ZunigaJosé M. Zuniga
José M. Zuniga
RSRenslow Sherer
Renslow Sherer
CBChris Beyrer
Chris Beyrer
JRJürgen Rockstroh
Jürgen Rockstroh
Background: Little is known globally about the perspectives of people living with HIV/AIDS (PLWHA) on perceived HIV-related stigma and its consequences. Methods: Cross-sectional study (January-March 2010) of perceived HIV-related stigma among PLWHA (N = 2035) using a standardized questionnaire. Findings: Thirty-seven percent of respondents reported loneliness as a result of their HIV status. Depression was reported by 27%. While 96% reported disclosing their HIV status to at least 1 person, 17% of patients who reported being in a long-term sexual relationship had not disclosed their status to their partner. Variables associated with perceived stigma were living in Asia-Pacific versus other regions (odds ratio [OR]: 2.77; 95% confidence interval [CI] 1.96-3.92); having experienced body/face changes; reported depression (OR: 1.25; 95% CI 1.11-1.38); and nondisclosure of HIV status (OR: 1.75; 95% CI 1.28-2.41). Conclusion: Thirty years into the HIV pandemic, perceived HIV stigma, isolation, and discrimination persist and are associated with loneliness and depression among PLWHA.

1 June 2021 in The Lancet Public Health
Verified
Journal Article
Open access
JDJohnathan H Duff
Johnathan H Duff
ALAnicca Liu
Anicca Liu
JSJorge Saavedra
Jorge Saavedra
JBJacob N Batycki
Jacob N Batycki
KMKendra Morancy
Kendra Morancy
JSJosé Szapocznik
José Szapocznik
As shown by COVID-19, infectious diseases with a pandemic potential present a grave threat to health and wellbeing. Although the International Health Regulations provide a framework of binding legal obligations for pandemic prevention, preparedness, and response, many countries do not comply with these regulations. There is a need for a renewed framework for global collective action that ensures conformity with international regulations and promotes effective prevention and response to pandemic infectious diseases. This Health Policy identifies the necessary characteristics for a new global public health security convention designed to optimise prevention, preparedness, and response to pandemic infectious diseases. We propose ten recommendations to strengthen global public health governance and promote compliance with global health security regulations. Recommendations for a new global public health security convention include greater authority for a global governing body, an improved ability to respond to pandemics, an objective evaluation system for national core public health capacities, more effective enforcement mechanisms, independent and sustainable funding, representativeness, and investment from multiple sectors, among others. The next steps to achieve these recommendations include assembling an invested alliance, specifying the operational structures of a global public health security system, and overcoming barriers such as insufficient political will, scarcity of resources, and individual national interests.

1 July 2017 in The Lancet
Verified
Journal Article
Closed access
RGReuben Granich
Reuben Granich
BWBrian Williams
Brian Williams
JMJulio Montaner
Julio Montaner
José M. ZunigaJosé M. Zuniga
José M. Zuniga

23 February 2012 in Journal of the International Association of Physicians in AIDS Care
Verified
Journal Article
Closed access
PDF file
JNJean B. Nachega
Jean B. Nachega
CMChelsea Morroni
Chelsea Morroni
José M. ZunigaJosé M. Zuniga
José M. Zuniga
MSMauro Schechter
Mauro Schechter
JRJürgen Rockstroh
Jürgen Rockstroh
RSRenslow Sherer
Renslow Sherer
Background: Little is known about patients' health literacy regarding antiretroviral therapy (ART) adherence and drug resistance and patient–provider communication about these topics. Design and Methods: The AIDS Treatment for Life International Survey was a multicountry cross-sectional study (January-March 2010) including 2035 HIV-infected adults. A 40-minute interview was conducted using a standardized self-report adherence questionnaire. Results: Overall, 57% of patients reported a 30-day recall of 100% adherence (Latin America: 89%; Africa: 73% vs North America: 45% and Asia Pacific: 47%; P < .01). Overall, 18% identified HIV drug resistance as a “good thing” in North America (35%) and Africa (24%). Only 71% said their health care providers had offered practical recommendations about adherence, 62% of the patients in North America and 80% in Latin America and Africa. Conclusions: Optimal ART adherence remains a challenge globally. There is a critical need to improve patient–provider communication about the importance of ART adherence and its benefits for patient’s health.

10 May 2013 in Journal of the International Association of Providers of AIDS Care (JIAPAC)
Verified
Journal Article
Open access
KMKenneth Mayer
Kenneth Mayer
BGBrian Gazzard
Brian Gazzard
José M. ZunigaJosé M. Zuniga
José M. Zuniga
KAK. Rivet Amico
K. Rivet Amico
JAJane Anderson
Jane Anderson
PSPapa Salif Sow
Papa Salif Sow
In the context of emerging evidence related to preexposure prophylaxis and HIV treatment as prevention, an evidence summit was held in mid-2012 to discuss the current state of the science and to provide a platform for consensus building around whether and how these prevention strategies might be implemented globally. Health care providers, researchers, policy makers, people living with HIV/AIDS, and representatives of government authorities, donor agencies, pharmaceutical companies, advocacy organizations, and professional associations attended from 52 countries. An international advisory committee was convened to identify key messages and recommendations based upon the data presented and discussed at the summit. The advisory committee further worked to develop this consensus statement meant to assist relevant stakeholders in taking stock and mapping out a route forward to enhance the HIV prevention armamentarium.